An investigation for investors in Edge Therapeutics, Inc. (NASDAW:EDGE) shares over potential securities laws violations by Edge Therapeutics, Inc was announced.
San Diego, CA -- (SBWIRE) -- 04/23/2018 -- Edge Therapeutics, Inc. is under investigation over possible securities laws violations.
Investors who purchased shares of Edge Therapeutics, Inc. (NASDAW:EDGE), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Edge Therapeutics, Inc. (NASDAW:EDGE) concerning whether a series of statements by Edge Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On March 28, 2018, Berkeley Heights, NJ based Edge Therapeutics disclosed, "that a pre-specified interim analysis on data from the Day 90 visit of the first 210 subjects randomized and treated in the Phase 3 NEWTON 2 study of EG-1962 demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study's primary endpoint, if the study is fully enrolled." As a result, the Data Monitoring Committee "recommended that the study be stopped based on its conclusion that the study has a low probability of meeting its primary endpoint." Based on the DMC recommendation, Edge Therapeutics stated that it has decided to discontinue the Phase 3 NEWTON 2 study. Shares of Edge Therapeutics, Inc. (NASDAW:EDGE) declined on April 3, 2018 to as low as $0.95 per share.
Those who purchased shares of Edge Therapeutics, Inc. (NASDAW:EDGE) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego